Zhaoke Ophthalmology Limited (HKG:6622)
2.500
+0.015 (0.60%)
Sep 18, 2026, 3:45 PM HKT
Zhaoke Ophthalmology Revenue
Zhaoke Ophthalmology had revenue of 18.83M CNY in the half year ending June 30, 2026, a decrease of -62.17%. This brings the company's revenue in the last twelve months to 35.00M, down -1.02% year-over-year. In the year 2025, Zhaoke Ophthalmology had annual revenue of 31.97M, down -53.88%.
Revenue (ttm)
35.00M CNY
Revenue Growth
-1.02%
P/S Ratio
33.95
Revenue / Employee
122.80K CNY
Employees
285
Market Cap
1.37B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 31.97M | -37.35M | -53.88% |
| Dec 31, 2024 | 69.32M | 50.57M | 269.73% |
| Dec 31, 2023 | 18.75M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hangzhou Jiuyuan Genetic Biopharmaceutical | 1.50B |
| Mabpharm | 888.77M |
| Shandong Boan Biotechnology | 720.87M |
| Guangzhou Innogen Pharmaceutical Group | 176.96M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 170.32M |
| CANbridge Pharmaceuticals | 64.28M |
| Beijing Biostar Pharmaceuticals | 63.74M |
| SinoMab BioScience | 6.28M |